Stripe, Anthropic, and OpenAI Launch $500 Million Nonprofit to End Respiratory Infections

A century ago, waterborne diseases such as cholera, typhoid, and dysentery caused massive suffering and economic damage.

Stripe, Anthropic, and OpenAI Launch 0 Million Nonprofit to End Respiratory Infections They were endemic, sparked periodic epidemics, and were widely viewed as an unavoidable part of life. Through a combination of clean water infrastructure, sanitation advances, and pharmaceuticals, humanity largely eliminated this threat in much of the world within decades.

Today, respiratory viruses — including those causing the common cold, influenza, and other illnesses — impose a comparable burden. They remain endemic, trigger seasonal surges, and are often dismissed as minor inconveniences. A new $500 million philanthropic initiative called Intercept, backed by Stripe, Anthropic, the OpenAI Foundation, and other major donors, aims to change that.

Launched on June 24, 2026, Intercept seeks to radically reduce — and eventually eliminate — the burden of respiratory infections through two complementary technological approaches: broad-spectrum preventatives (medicines) and air-cleaning technologies.

The Scale of the Problem

Stripe, Anthropic, and OpenAI Launch 0 Million Nonprofit to End Respiratory Infections Healthy people typically spend 15–25 days per year — roughly 5% of their lives — ill with respiratory infections. In 2021 alone, there were an estimated 12.8 billion such infections globally. These illnesses lead to serious lower respiratory disease in tens of millions of cases annually and contribute significantly to deaths from major causes.

Beyond immediate symptoms, respiratory infections carry long-term risks, including increased chances of asthma, heart attacks, heart failure, dementia, Alzheimer’s disease, and other conditions. They also impose a massive economic toll, with annual global productivity losses estimated at around $600 billion (roughly 0.6% of global GDP) in non-pandemic years.

Routine respiratory viruses also represent a critical vulnerability for future pandemics, both natural and engineered.

Why a Coordinated Effort Is Needed Now

Stripe, Anthropic, and OpenAI Launch 0 Million Nonprofit to End Respiratory Infections Last August, Stripe hosted a symposium with approximately 40 leading scientists, pharmaceutical R&D leaders, biotech investors, and regulatory experts. The group concluded there is moderate optimism that broad protection against most respiratory viruses is technically feasible, thanks to advances in protein design, immunology, biological datasets, and platform technologies.

However, two major barriers have held progress back:

Technical complexity: Over 200 distinct viruses cause the common cold and related illnesses, spanning multiple families and constantly mutating.
Funding gap: These pathogens fall between traditional philanthropic priorities (focused on high-mortality diseases) and commercial incentives (which favor treatments for severe or rare conditions over broad population health).

No single intervention can achieve population-level impact on its own.

Even a hypothetical medicine offering >90% protection against >90% of respiratory viruses would likely achieve only around 60% real-world uptake — a realistic ceiling based on current vaccination rates. This would fall short of the threshold needed for strong population-level protection against sustained transmission.

Intercept’s Dual Strategy

Intercept will fund work along two parallel tracks designed to work together and drive the effective reproduction number (Re) of these viruses below 1 in high-risk settings.

1. Broad-Spectrum Preventatives (BSPs)
These are medicines — vaccines, nasal sprays, pills, or other formats — that protect individuals against a wide range of respiratory viruses simultaneously (rhinoviruses, influenza, coronaviruses, and others).

Target profile: Safe, well-tolerated products that prevent more than 75% of symptomatic infections, require few doses, are easy to administer, and have a realistic path to ~60% population uptake.

Promising approaches include:

Physical barrier formulations, such as nasal sprays or gels containing high-affinity virus-trapping proteins (e.g., lectins or other engineered binders) that intercept viruses before they can infect cells.
Engineered innate immunity modulators (improved interferon-like proteins).
Host-directed antivirals and direct-acting agents targeting conserved viral features.
T-cell focused strategies for mucosal immunity.

Intercept plans a two-track funding model: equity investments in more advanced clinical-stage projects (aiming for Phase 2 data in 3–4 years) and grants for earlier-stage work leading toward commercialization in 5–7+ years.

2. Air-Cleaning Technologies (ACTs)
These technologies reduce the concentration of infectious aerosols in indoor environments by more than 75%, with a path to economical, widespread deployment in high-transmission spaces such as offices, schools, and public transit.

Promising options include:

Air filtration systems (ducted or portable).
Far-UVC antimicrobial lights, which inactivate pathogens in the air and on surfaces without harming human skin or eyes. These have accumulated substantial safety and efficacy data over the past decade.
Antimicrobial vapors (such as triethylene glycol or propylene glycol), which have been used successfully in emergency settings but require further study for continuous, everyday use.

Filtration is already proven in principle but needs additional validation and scaling for high-risk environments. Far-UVC and vapors offer complementary inactivation methods.

Timeline and Path to Impact

Intercept’s horizon is approximately 4–7 years to advance technologies to late-stage clinical or real-world testing. Once products are sufficiently de-risked (e.g., through Phase 2 data or strong efficacy evidence), the commercial sector — pharmaceutical companies, manufacturers, and building technology firms — is expected to take over scaling, production, and widespread deployment.

The initiative combines philanthropic grants and targeted investments. It has already attracted anchor funding from Stripe, Anthropic, the OpenAI Foundation, Flu Lab, individuals from Jane Street Capital, Bill Gates (through a philanthropic entity), and others.

A Historic Opportunity

Just as centralized action transformed waterborne diseases from inevitable threats into rare occurrences, Intercept represents a focused, well-resourced effort to apply 21st-century science and engineering to respiratory infections.

By advancing both personal protection (through convenient medicines) and environmental control (through better indoor air), the initiative aims to make routine colds and flu far less common — and potentially relegate them to the history books alongside cholera and typhoid.

The science is promising, the need is clear, and the backers have demonstrated a willingness to tackle ambitious, long-term public goods problems. If successful, Intercept could deliver one of the most significant improvements in everyday human health and productivity in generations.